Evidence map›Paper›PMID 26905099›Full record

ReviewTissue engineering. Part B, Reviews2016

Update on Renal Replacement Therapy: Implantable Artificial Devices and Bioengineered Organs.

Chiara Attanasio, Marcela T Latancia, Leo E Otterbein, Paolo A Netti

Abstract readReview
In one paragraph

Review in Tissue engineering. Part B, Reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Physiology and technology for the ICU in vivo.Critical care (London, England) · 2019
    Review
  5. Article
  6. Article
  7. Review
  8. New Phase of Growth for Xenogeneic-Based Bioartificial Organs.International journal of molecular sciences · 2016
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chiara Attanasio1 Center for Advanced Biomaterials for Health Care, IIT@CRIB, Istituto Italiano di Tecnologia , Napoli, Italy .
Marcela T Latancia2 Department of Surgery, Transplant Institute , Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Leo E Otterbein2 Department of Surgery, Transplant Institute , Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Paolo A Netti1 Center for Advanced Biomaterials for Health Care, IIT@CRIB, Istituto Italiano di Tecnologia , Napoli, Italy .

Funding

Sepsis and the benefits of permissive hypoxiaK08GM134220 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SHAEFI, SHAHZAD · 2019 to 2022
$775k
NIGMS NIH HHS K08 GM134220
6 · The paper itself

Abstract

Recent advances in the fields of artificial organs and regenerative medicine are now joining forces in the areas of organ transplantation and bioengineering to solve continued challenges for patients with end-stage renal disease. The waiting lists for those needing a transplant continue to exceed demand. Dialysis, while effective, brings different challenges, including quality of life and susceptibility to infection. Unfortunately, the majority of research outputs are far from delivering satisfactory solutions. Current efforts are focused on providing a self-standing device able to recapitulate kidney function. In this review, we focus on two remarkable innovations that may offer significant clinical impact in the field of renal replacement therapy: the implantable artificial renal assist device (RAD) and the transplantable bioengineered kidney. The artificial RAD strategy utilizes micromachining techniques to fabricate a biohybrid system able to mimic renal morphology and function. The current trend in kidney bioengineering exploits the structure of the native organ to produce a kidney that is ready to be transplanted. Although these two systems stem from different technological approaches, they are both designed to be implantable, long lasting, and free standing to allow patients with kidney failure to be autonomous. However, for both of them, there are relevant issues that must be addressed before translation into clinical use and these are discussed in this review.

Indexed as

Renal Replacement TherapyBioengineeringHumansKidney Failure, ChronicQuality of LifeRegenerative Medicine

Identifiers

PMID26905099
PMCPMC13215044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.